NCT00003274View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 1998

Primary Completion Date

September 30, 2001

Study Completion Date

November 30, 2002

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

gp100 antigen

BIOLOGICAL

incomplete Freund's adjuvant

BIOLOGICAL

sargramostim

BIOLOGICAL

tyrosinase peptide

Trial Locations (2)

90033-0804

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

48109-0752

University of Michigan Comprehensive Cancer Center, Ann Arbor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER

NCT00003274 - Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery | Biotech Hunter | Biotech Hunter